AIMS: Vimentin, a type III intermediate filament, is upregulated during epithelial-mesenchymal transition and tumor progression. Vimentin is surface-expressed on cells involved in inflammation; the function remains unknown. We investigated the expression of surface vimentin on cancer cells and evaluated targeting nanoparticles to tumors exploiting vimentin. MATERIALS & METHODS: Cowpea mosaic virus nanoparticles that interact with surface vimentin were used as probes. Tumor homing was tested using the chick chorioallantoic membrane model with human tumor xenografts. RESULTS & DISCUSSION: Surface vimentin levels varied during cell cycle and among the cell lines tested. Surface vimentin expression correlated with cowpea mosaic virus uptake, underscoring the utility of cowpea mosaic virus to detect invasive cancer cells. Targeting to tumor xenografts was observed; homing was based on the enhanced permeability and retention effect. Our data provide novel insights into the role of surface vimentin in cancer and targeting nanoparticles in vivo.
AIMS: Vimentin, a type III intermediate filament, is upregulated during epithelial-mesenchymal transition and tumor progression. Vimentin is surface-expressed on cells involved in inflammation; the function remains unknown. We investigated the expression of surface vimentin on cancer cells and evaluated targeting nanoparticles to tumors exploiting vimentin. MATERIALS & METHODS:Cowpea mosaic virus nanoparticles that interact with surface vimentin were used as probes. Tumor homing was tested using the chick chorioallantoic membrane model with humantumor xenografts. RESULTS & DISCUSSION: Surface vimentin levels varied during cell cycle and among the cell lines tested. Surface vimentin expression correlated with cowpea mosaic virus uptake, underscoring the utility of cowpea mosaic virus to detect invasive cancer cells. Targeting to tumor xenografts was observed; homing was based on the enhanced permeability and retention effect. Our data provide novel insights into the role of surface vimentin in cancer and targeting nanoparticles in vivo.
Authors: Pratik Singh; Duane Prasuhn; Robert M Yeh; Giuseppe Destito; Chris S Rae; Kent Osborn; M G Finn; Marianne Manchester Journal: J Control Release Date: 2007-04-13 Impact factor: 9.776
Authors: Clorissa L Washington-Hughes; Yixing Cheng; Xinrui Duan; Li Cai; L Andrew Lee; Qian Wang Journal: Mol Pharm Date: 2012-10-11 Impact factor: 4.939
Authors: Alaa A A Aljabali; Sourabh Shukla; George P Lomonossoff; Nicole F Steinmetz; David J Evans Journal: Mol Pharm Date: 2012-08-06 Impact factor: 4.939
Authors: Karin L Lee; Sourabh Shukla; Mengzhi Wu; Nadia R Ayat; Caroline E El Sanadi; Amy M Wen; John F Edelbrock; Jonathan K Pokorski; Ulrich Commandeur; George R Dubyak; Nicole F Steinmetz Journal: Acta Biomater Date: 2015-03-10 Impact factor: 8.947